Wird geladen...
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada
BACKGROUND: In Canada and elsewhere, pazopanib and sunitinib—tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors—are recommended as first-line treatment for patients with metastatic renal cell carcinoma (mrcc). A large randomized noninferiority trial of pazopanib ve...
Gespeichert in:
| Veröffentlicht in: | Curr Oncol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Multimed Inc.
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4974040/ https://ncbi.nlm.nih.gov/pubmed/27536183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.23.2244 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|